专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023016932A1 METHOD FOR CHARACTERIZATION OF CANCER 审中-公开
公开(公告)号：WO2023016932A1
公开(公告)日：2023-02-16
申请号：PCT/EP2022/072034
申请日：2022-08-04
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS , UNIVERSITÄT HEIDELBERG
发明人： SAHM, Felix , SILL, Martin , VON DEIMLING, Andreas , PFISTER, Stefan , JONES, David , PATEL, Areeba , DOGAN, Helin , LOOSE, Matt
IPC分类号： G16B30/00 , G16B40/10 , G16B40/20
摘要： The present disclosure relates to a computer-implemented method for cancer diagnosis, comprising: a) selectively sequencing polymers of a biological sample according to at least one target gene site by translocating the polymers through nanopores of a nanopore sequencing system, including: (i) analyzing an initial nucleotide sequence of a first polymer of the biological sample while the first polymer is translocating through a nanopore of the nanopore sequencing system to determine whether the initial nucleotide sequence corresponds to the at least one target gene site; and (ii) continuing the sequencing of the first polymer to obtain measurement data of the first polymer only if the initial nucleotide sequence of the first polymer corresponds to the at least one target gene site; b) determining, based on the measurement data, a biological state of a nucleotide sequence of the first polymer corresponding to the at least one target gene site; and c) classifying a cancer using a classification algorithm based on the biological state of the nucleotide sequence of the first polymer, wherein the classification algorithm is trained based on the at least one target gene site and biological state data pertaining to cancer types.

2. 发明申请

WO2022243502A1 INHIBITORS OF MITOFERRIN-2 FOR USE IN TREATING CANCER 审中-公开
公开(公告)号：WO2022243502A1
公开(公告)日：2022-11-24
申请号：PCT/EP2022/063693
申请日：2022-05-20
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS , UNIVERSITÄT HEIDELBERG
发明人： TSCHAHARGANEH, Darjus , KRIEG, Stephan
IPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/14 , C12N2310/20 , C12N2310/531 , C12Q1/6851 , C12Q1/6886 , C12Q2600/106 , C12Q2600/178
摘要： The present invention relates to an inhibitor of mitoferrin-2 for use in treating a cancer with reduced activity of mitoferrin-1 in a subject. The present invention also relates to a method for identifying an inhibitor of mitoferrin-2 comprising (a) contacting a (i) host cell with a reduced mitoferrin-1 activity and (ii) a host cell with a non-reduced mitoferrin-1 activity with a candidate inhibitor of mitoferrin-2, (b) determining growth and/or morphology of the host cells of step (a); (c) identifying an inhibitor of mitoferrin-2 if a growth arrest and/or abnormal morphology is/are detected in step (b) in the host cell having the reduced activity of mitoferrin- 1 but not in the host cell with the non-reduced activity of mitoferrin-1. The present invention further relates to a method for identifying a subject susceptible to cancer treatment by an inhibitor of mitoferrin-2, comprising (A) determining mitoferrin-1 activity in a sample of said subject, preferably a sample of cancer cells, and (B) identifying a patient susceptible to cancer treatment by an inhibitor of mitoferrin-2 based on determining step (A).

3. 发明申请

WO2022184824A2 CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1 审中-公开
公开(公告)号：WO2022184824A2
公开(公告)日：2022-09-09
申请号：PCT/EP2022/055394
申请日：2022-03-03
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： HALAMA, Niels , JÄGER, Dirk , SCHMIDT, Patrick
IPC分类号： A61K35/17 , A61K35/768 , A61P35/00 , C07K14/725 , C07K16/30 , C12N5/0783 , A61K39/00 , A61K2039/505 , A61K2039/5156 , C07K14/7051 , C07K16/3007 , C07K2317/622 , C07K2319/03 , C12N2501/515 , C12N2510/00 , C12N2750/14011 , C12N5/0636
摘要： The present invention relates to compositions, methods, uses and kits for combination therapies involving immunotherapies, such as adaptive cell therapy, e.g., T cell therapy, and an oncolytic virus (particularly parvovirus H-1), for treating subjects with cancer. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the cancer is a solid tumor or a hematological malignancy.

4. 发明申请

WO2022101449A1 INHIBITORS FOR USE IN TREATING LIVER DISORDERS 审中-公开
公开(公告)号：WO2022101449A1
公开(公告)日：2022-05-19
申请号：PCT/EP2021/081596
申请日：2021-11-12
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： HEIKENWÄLDER, Mathias , LI, Xin , RAMADORI, Pierluigi , HALLER, Dirk
IPC分类号： G01N33/50 , A61K38/55 , G01N33/574 , G01N33/68
摘要： The invention is based on the finding that endoplasmic reticulum (ER) stress signalling is associated with the pathogenesis of liver disorders such fatty liver, cirrhosis and hepatocellular carcinoma (HCC), and others. The invention identifies novel targets for liver disease therapy which are involved in ER stress signalling, and thereby pertains to compounds and compositions for medical uses, screening approaches to identify therapeutics as well as diagnostic approaches for the identification of disorders or the stratification of certain liver disease patient groups. The invention also pertains to the use of immune checkpoint inhibitors in combination with the compounds or compositions and/or in the treatment of endoplasmic reticulum (ER) stress signalling induced liver cancers.

5. 发明申请

WO2020169796A1 USE OF BMMF1 REP PROTEIN AS A BIOMARKER FOR BREAST CANCER 审中-公开
公开(公告)号：WO2020169796A1
公开(公告)日：2020-08-27
申请号：PCT/EP2020/054613
申请日：2020-02-21
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： BUND, Timo , DE VILLIERS-ZUR HAUSEN, Ethel-Michele , ZUR HAUSEN, Harald , ERNST, Claudia , TESSMER, Claudia
IPC分类号： G01N33/574
摘要： The present invention relates to the use of BMMF Rep-protein as biomarker for breast cancer.

6. 发明申请

WO2020161247A1 ANNEXIN-COATED PARTICLES 审中-公开
公开(公告)号：WO2020161247A1
公开(公告)日：2020-08-13
申请号：PCT/EP2020/053007
申请日：2020-02-06
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： KRAMMER, Peter , WEYD, Heiko , BODE, Kevin
IPC分类号： A61K9/50 , A61K9/127
摘要： The present invention relates to an annexin-coated particle, comprising a negatively charged phospholipid and an annexin non-covalently coupled thereto. The present invention further relates to a composition comprising an annexin-coated particle. Furthermore, the present invention relates to a product for use in a method of preventing or treating a disease selected from a chronic inflammatory disease, an autoimmune disease, an allergy, and a cancer, said product comprising an annexin-coated particle, and/or a composition. The present invention further relates to a method of preparing an annexin-coated particle.

7. 发明申请

WO2020008054A1 FUSED IMIDAZOLIUM DERIVATIVES FOR USE IN THE TREATMENT OF COLORECTAL CANCER 审中-公开
公开(公告)号：WO2020008054A1
公开(公告)日：2020-01-09
申请号：PCT/EP2019/068156
申请日：2019-07-05
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： ZHAN, Tianzuo , RAUSCHER, Benedikt , FAEHLING, Verena , BOUTROS, Michael
IPC分类号： C07D403/06 , A61K31/497 , A61P35/00
摘要： The present invention pertains to fused imidazolium derivatives, in particular 11-(2- methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H- naphtho(2,3-d)imidazolium bromide for use in the treatment of colorectal cancer (CRC). The invention provides the therapeutic application of such compounds in a patient subgroup of CRC, which is characterized by a consensus molecular subtype (CMS) 1.

8. 发明申请

WO2018087276A1 OR10H1 MODULATORS AND USES THEREOF 审中-公开
标题翻译： OR10H1调制器及其用途
公开(公告)号：WO2018087276A1
公开(公告)日：2018-05-17
申请号：PCT/EP2017/078856
申请日：2017-11-10
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： BECKHOVE, Philipp , MICHELS, Tillmann , KHANDELWAL, Nisit , BOUTROS, Michael , BREINIG, Marco , SORRENTINO, Antonio , VOLPIN, Valentina
IPC分类号： C07K14/705 , C07K16/28 , C12N15/113 , G01N33/574
摘要： The present invention pertains to novel modulators of resistance against T-cell mediated cytotoxic immune responses. The invention provides antagonists of immune escape mechanisms and therefore offers a novel approach for treating, or aiding a treatment, of various proliferative diseases such as cancerous diseases, in particular melanoma, pancreatic cancer and colorectal cancer. The invention specifically discloses the receptor Olfactory Receptor, Family 10, Subfamily H, Member 1 (OR10H1)as a checkpoint molecule in tumor resistance against cytotoxic T-cells. Provided is the inhibition of OR10H1 expression and/or function as a strategy for enhancing tumor susceptibility to a patients T-cell mediated immune response. Provided are antigen binding constructs for the detection of the OR10H1 protein, as well as inhibitory compounds, such as siRNA/shRNA molecules targeting OR10H1 and anti-OR10H1 antibodies, forimpairing the immune escape mediated by OR10H1. The invention furthermore provides screening methods for the identification of novel cancer therapeutics based on the modulation OR10H1 expression/function, diagnostic methods for the detection of immune resistance of a tumor to cytotoxic T-cell responses, as well as pharmaceutical compositions and diagnostic kits for performing these methods.
摘要翻译：本发明涉及抗T细胞介导的细胞毒性免疫应答的新型调节剂。本发明提供了免疫逃避机制的拮抗剂，因此提供了治疗或帮助治疗各种增殖性疾病例如癌性疾病，特别是黑素瘤，胰腺癌和结直肠癌的新方法。本发明特别公开了受体嗅觉受体家族10亚族H成员1（OR10H1）作为肿瘤抗细胞毒性T细胞的关卡分子。提供了OR10H1表达和/或功能的抑制作为增强对患者T细胞介导的免疫应答的肿瘤易感性的策略。提供了用于检测OR10H1蛋白的抗原结合构建体，以及抑制性化合物，例如靶向OR10H1和抗-OR10H1抗体的siRNA / shRNA分子，用于阻止OR10H1介导的免疫逃逸。本发明还提供了用于鉴定基于调节OR10H1表达/功能的新型癌症治疗剂的筛选方法，用于检测肿瘤对细胞毒性T细胞应答的免疫抗性的诊断方法，以及用于进行表达的药物组合物和诊断试剂盒这些方法。

9. 发明申请

WO2018065607A1 CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN RELATED PEPTIDASE 6 (KLK6) 审中-公开
标题翻译：化学物质抑制人类KALIKREIN相关肽酶6（KLK6）的酶活性
公开(公告)号：WO2018065607A1
公开(公告)日：2018-04-12
申请号：PCT/EP2017/075552
申请日：2017-10-06
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： MILLER, Aubry , SCHÜLER, Peter , DE VITA, Elena , GUNKEL, Nikolas
IPC分类号： C07D403/12 , C07D231/40 , C07D209/08 , C07D401/12 , C07D405/12 , C07D409/12 , A61K31/4155 , A61K31/405 , A61K31/4439 , A61K31/4178 , A61K31/506 , C07C235/00
CPC分类号： C07D403/12 , A61K31/404 , A61K31/415 , C07D209/08 , C07D231/40 , C07D401/12 , C07D405/12 , C07D409/12
摘要： The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein related peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds or pharmaceutical compositions.
摘要翻译：本发明涉及适用于治疗与激肽释放酶相关肽酶6过表达有关的疾病的化合物和含有这些化合物的药物组合物。本发明进一步涉及包含此类化合物或药物组合物的成套药盒。

10. 发明申请

WO2017140793A1 MODULATORS OF CCR9 FOR TREATING TUMOR RESISTANCE TO IMMUNE RESPONSES 审中-公开
标题翻译： CCR9调节剂用于治疗免疫应答的肿瘤抵抗力
公开(公告)号：WO2017140793A1
公开(公告)日：2017-08-24
申请号：PCT/EP2017/053521
申请日：2017-02-16
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： KHANDELWAL, Nisit , BECKHOVE, Philipp , BOUTROS, Michael , BREINIG, Marco , MICHELS, Tillmann
IPC分类号： A61K31/4375 , A61K31/517 , A61K31/713 , A61K39/00 , A61K45/06 , G01N33/50
CPC分类号： A61K31/4375 , A61K31/517 , A61K31/713 , A61K45/06 , G01N33/50 , G01N33/5011 , G01N33/505 , G01N33/6893 , A61K2300/00
摘要： The present invention pertains to novel modulators of tumor resistance against T-cell mediated cytotoxic immune responses. The invention provides antagonists of tumor immune escape mechanisms and methods and other aspects related thereto, and therefore provides novel approaches for treating or aiding a treatment of various cancerous diseases and/or the diagnosis thereof. The invention specifically discloses C-C chemokine receptor type 9 (CCR9) as a checkpoint molecule in tumor resistance against cytotoxic T-cells. Provided is the inhibition of CCR9 expression, CCR9 signalling and/or CCR9-T-Cell interaction and inhibitors or antagonists thereof. In particular aspects, the invention provides combination therapeutics and/or therapies involving such inhibitors or antagonists. The invention furthermore provides screening methods for novel cancer therapeutics modulating CCR9 action, diagnostic approaches to detect cancer resistance to cytotoxic T-cells as well as pharmaceutical compositions and diagnostic kits for performing, for use with or related to these methods.
摘要翻译：本发明涉及针对T细胞介导的细胞毒性免疫应答的肿瘤抗性的新型调节剂。本发明提供了肿瘤免疫逃避机制和方法及其相关方面的拮抗剂，并因此提供了治疗或帮助治疗各种癌性疾病和/或其诊断的新方法。本发明特别公开了C-C趋化因子受体9型（CCR9）作为肿瘤抗细胞毒性T细胞的关卡分子。提供了CCR9表达，CCR9信号传导和/或CCR9-T细胞相互作用及其抑制剂或拮抗剂的抑制。在具体的方面，本发明提供涉及这种抑制剂或拮抗剂的组合治疗剂和/或疗法。本发明还提供了用于调节CCR9作用的新型癌症治疗剂的筛选方法，检测对细胞毒性T细胞的癌症抗性的诊断方法以及用于与这些方法一起使用或与之相关的药物组合物和诊断试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式